William Hoi Hong Li

Statistics

Publications

Citations

950

H-Index

Active since

2011

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

William Hoi Hong Li is an author at GlaxoSmithKline (United States) specializing in drug discovery, protein kinase inhibitors, and hit-to-lead optimization.

Publications per year

2011–2013

Publications

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng et al. · Journal of Medicinal Chemistry · 2012 · 619 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development

Jeffrey M. Axten, Stuart P. Romeril, Arthur Y. L. Shu et al. · ACS Medicinal Chemistry Letters · 2013 · 230 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Concerted vs Stepwise Mechanisms in Dehydro-Diels–Alder Reactions

Aida Ajaz, Alexander Z. Bradley, Richard C. Burrell et al. · The Journal of Organic Chemistry · 2011 · 101 citations

Natural Sciences, Chemistry, Computational Chemistry +12

1–3 of 3